We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Antibody responses to SARS‐CoV‐2 vaccination in patients with acute myeloid leukaemia and high risk MDS on active anti‐cancer therapies.
- Authors
Chan, Wei Yee; Zhu, Catherine; Sanchez, Emilie; Gupta, Rajeev; Fielding, Adele K.; Khwaja, Asim; Payne, Elspeth M.; O'Nions, Jenny
- Abstract
We report SARS-CoV-2 antibody responses following vaccination in a UK cohort of AML and HR-MDS patients all receiving, or having recently completed SACT, and stratified by prior SARS-CoV-2 infection. (D) Seroconversion rates in patients with no previous SARS-CoV-2 infection, after one and two doses of vaccine (paired predose, post first dose and second dose) in all patients. Encouraging seroconversion rates to SARS-CoV-2 vaccination in acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) patients have been reported in large cohort studies1-4; however, the majority of these patients were not receiving active systemic anti-cancer therapy (SACT) and its impact on vaccine responses remains to be fully elucidated.
- Subjects
ACUTE myeloid leukemia; ANTINEOPLASTIC agents; ANTIBODY formation; HIV seroconversion; SARS-CoV-2; VACCINATION
- Publication
British Journal of Haematology, 2022, Vol 198, Issue 3, p478
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.18248